Spinosin and 6'''-Feruloylspinosin protect the heart against acute myocardial ischemia and reperfusion in rats

MINHUA GU1,2, PEIKUN HE1, CHENFEI LYU3, XIAOYU LIU1, YULONG XU1, SAIBO CHENG1, YONG GU3 and YUHUA JIA1

1School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510515;
2Department of Chinese Medicine, Dongsheng Hospital, Guangzhou, Guangdong 510120;
3Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China

Received February 1, 2019; Accepted August 30, 2019

Abstract. Investigating active compounds from Chinese herbal medicine that can rescue myocardial cells is a good approach to preserve cardiac function. Several herbal formulae containing Semen Ziziphi Spinossae (SZS), also called Suanzaoren in Chinese, are clinically effective in the treatment of patients with acute myocardial infarction (AMI). The present study aimed to investigate the cardioprotective effects of spinosin and 6'''-feruloylspinosin, two flavonoid glycosides from SZS, in a rat model of myocardial ischemia and reperfusion. The left anterior descending artery (LAD) was occluded to induce myocardial ischemia. Spinosin or 6'''-feruloylspinosin (5 mg/kg) was intraperitoneally injected into rats 30 min before LAD ligation. The protein levels of myocardial enzymes in the serum, the extent of tissue injury and the rate of apoptosis were examined after AMI in rats with or without pretreatment with spinosin or 6'''-feruloylspinosin. Western blotting was performed to investigate the potential mechanisms underlying the function of these two flavonoid glycosides. The present results suggested that pretreatment with spinosin or 6'''-feruloylspinosin significantly attenuated myocardial tissue injury, and reduced myocardial enzyme release and cell apoptosis in AMI rats. In addition, spinosin treatment increased light chain 3B-II and 6'''-feruloylspinosin, and reduced p62, indicating that autophagy was promoted after drug treatments. Treatments of spinosin and 6'''-feruloylspinosin led to the reduction of glycogen synthase kinase-3β (GSK3β) phosphorylation at Tyr216, and the increase of peroxisome proliferator-activated receptor γ coactivator (PGC)-1α and its downstream signaling proteins, including nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and hemeoxygenase1 (HO-1). The present data suggested that SZS flavonoids could protect myocardial cells against acute heart ischemia-reperfusion, probably via the inhibition of GSK3β, which increased autophagy and the activity of the PGC-1α/Nrf2/HO-1 pathway.

Introduction

Acute myocardial infarction (AMI) is one of leading causes of death and has become a major public health issue in both developed and developing countries (1). The aging population is increasing, and the AMI incidence rate is projected to increase (1). Early re-establishment of coronary reperfusion by thrombolytic therapy and endovascular intervention are the most effective strategies to reduce infarct size and preserve cardiac function (2). However, there are many patients with AMI who cannot benefit from coronary revascularization due to the time windows of thrombolysis and endovascular intervention, hemorrhagic tendency or reperfusion (2). Identifying cardioprotective reagents that can rescue injured myocardial cells is an important approach to preserve cardiac function.

Chinese herbal medicine has been used for thousands of years to treat diseases in human, and has recently attracted increasing attention in drug discovery research. Semen Ziziphi Spinossae (SZS), also called Suanzaoren in Chinese, is the seed of plant Ziziphus jujuba Mill. Spinosa Huex HF Chou, also known as jujube seeds. Generally, SZS is considered as a hypnotic-sedative herb and oriental medicine practitioners typically use it to treat insomnia and anxiety (3). Meanwhile, several formulations that containing SZS, such as Dingxin Recipe and Shensong Yangxin Capsule, were shown to exhibit cardioprotective effects and prevent ischemia/reperfusion-induced arrhythmias (2,4). However, whether SZS or its components provide cardioprotective effects remains to be elucidated.
SZS contains more than 50 bioactive compounds, including saponins, cyclopeptide alkaloids and C-glycoside flavonoids. Among them, 2''-β-D-glucopyranosyl swertisin (spinosin) and 6''-feruloylspinosin (Fig. 1), two C-glycoside flavonoids, are used in healthcare products in Western countries and have been shown to exhibit pharmacological activities such as anxiolytic and hypnotic effects (5). In addition, spinosin was reported to increase neurogenesis, ameliorate memory deficit and enhance cognitive performance in mice (6,7). A recent study suggested that spinosin exhibits neuroprotective effects in a mouse model of Alzheimer's disease (8). However, whether the two C-glycoside flavonoids have cardioprotective effects during ischemia-reperfusion injury remains to be elucidated.

The present study investigated the therapeutic potential of spinosin and 6''-feruloylspinosin in a rat model of AMI. The cardioprotective effect of these two flavonoids and their underlying mechanisms were studied and compared.

Materials and methods

Experimental animals and ethics statement. Male Wistar albino rats (8-10 weeks) weighing 250-300 g were obtained from the Experimental Animal Center, Southern Medical University (Guangzhou, China). All animals were housed under a 12-h light/dark cycle with an average temperature of 23˚C and 40-60% humidity. Food and water were provided *ad libitum*. Randomization was performed by a third person unrelated to the study using a randomization table. All procedures were approved by the Ethics committee on Animal Experiments, Southern Medical University (approval no. L20170355) and followed the National Guidelines for Animal Experimentation (https://oacu.oir.nih.gov/animal-research-advisory-committee-guidelines).

Animals were acclimatized and fed until surgery. All efforts were made to minimize the number of animals used and their suffering.

Establishment of a rat model of AMI. Occlusion of the left anterior descending coronary artery (LAD) was employed to induce myocardial infarction to mimic human AMI, as previously described (9). Briefly, after being anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg, Merck KGaA), the rats received mechanical ventilation with a volume-controlled rodent respirator (RWD Life Science Co., Ltd.). Then, the myocardial ischemia-reperfusion injury rat model was established by LAD ligation for 30 min followed by 1 h reperfusion. Rats were placed on a heating pad to maintain a temperature of 37˚C during surgery. The rats were treated only with chest opening and threading but without LAD ligation. At the end of the reperfusion period, the animals were euthanized by intraperitoneal injection of 200 mg/kg sodium pentobarbital, and blood and heart tissues were collected for ELISA, hematoxylin and eosin (HE) or TUNEL staining, and western blot analysis.

Electrocardiogram and triphenyl tetrazolium chloride (TTC) staining were performed to verify if the AMI model had been successfully established. Before surgery onset, acupuncture needles were penetrated into the rat skin of four limbs, and then were connected to Pclab-530c biomedical information acquisition system (Pclab-530c; Beijing Microsignalstar) according to the manufacturer's protocol. Standardized II lead was observed. For TTC staining, the heart tissue was placed into 1% TTC (Sigma-Aldrich, St. Louis, MO) dissolved in 1X phosphate buffered saline in flask. After 10 min at 37˚C, the heart sections were imaged using a digital camera.

Drug administration. Animals were randomly assigned to four groups: i) Sham group; ii) vehicle group (Veh); iii) spinosin treated group (SP); and iv) 6''-feruloylspinosin treated group (FS). Spinosin and 6''-feruloylspinosin were dissolved in DMSO and further diluted in saline. Drugs were intraperitoneally administered (5 mg/kg) 30 min before surgery. The dose and treatment methods were in accordance with two previous studies that focused on the effects of flavonoids on myocardial ischemia-reperfusion in rats (10,11). The equal volume of DMSO-saline solution was used to treat AMI rats as vehicle control. A total of 48 rats were used in the study, with 12 rats in each group.

ELISA assay for determining the level of cardiac troponin I (cTnI) in sera. After reperfusion, serum from each rat in four groups was collected and centrifuged for determining the level of cTnI by a commercial ELISA kit (JLC2389, Shanghai Jiang Kang Biotech) according to the manufacturer’s instructions.

Evaluation of lactate dehydrogenase (LDH) activity. Sera were also used to detect LDH activity. LDH catalyzes lactic acid to produce pyruvate which reacts with 2,4-dinitrophenylhydrazine to yield pyruvate dinitrophenylhydrazone, exhibiting a brown color in alkaline solution and which can be quantified by colorimetric analysis (12). A commercial kit was purchased to detect LDH activity (Nanjing Jiancheng Bioengineering Institute) in accordance the manufacturer's instructions. The absorbance was measured at 450 nm using a microplate reader (Bio-Rad Laboratories, Inc.).

HE staining of histological sections. The heart tissues were isolated to observe the integrity and injury in different groups by HE staining. Briefly, after ischemia and reperfusion, rat hearts were isolated and the heart tissues were fixed in 4% paraformaldehyde overnight at room temperature, and then dehydrated by passing through gradient concentrations of ethanol (80% for 2 h, 90% for 2 h, 95% overnight, 100% for 0.5, 0.5 and 1 h) at room temperature, followed by embedding in paraffin wax. The paraffin-embedded samples were then sectioned at 4 µm for staining with Mayer's Hematoxylin (H8070, Solarbio Life Sciences, Beijing, China) for 10 min and then by 0.5% aqueous eosin (DH0050, Leigene Biotech, Beijing, China) for 3 min at room temperature. With this method, nucleus and other acidic structures are stained blue, while cytoplasm is stained red. Images were acquired using a light microscope at x50 or x400 magnification (Leica Microsystems GmbH).

TUNEL staining on heart specimen. Rat heart tissues from various groups were collected to determine cell apoptosis using DeadEnd Fluorometric TUNEL System (Promega Corporation). A portion of heart tissues were fixed in 4% paraformaldehyde overnight at room temperature and then sectioned at 10 µm thickness for TUNEL staining of fragmented DNA.
according to manufacturer’s instructions. The stained specimen was then mounted using Fluoroshield Mounting Medium with DAPI (Abcam) to stain all nuclei, followed by observation under a fluorescent microscope (Olympus Corporation). Then, three sections of each heart were observed, and the average TUNEL-positive cells were counted using ImageJ 1.48v (National Institutes of Health), to the maximum extent possible, to keep results uniform and accurate. The total number of positive nuclei was determined by counting all the labeled nuclei present in the entire specimen.

**Western blot analysis.** Heart tissues of the same regions were homogenized in RIPA lysis buffer (Leigen Biotech Co. Ltd.) containing protease and phosphatase inhibitors (MedChemExpress). Total proteins of each sample were quantified by a BCA quantification kit (FD2001, Fdbio Science). The expression of each protein in these samples was analyzed by Western blot, according to a previous literature (13). In brief, after being denatured in loading buffer, a total of 30 µg proteins in each sample were separated by SDS-PAGE on 8-10% gels and then transferred to polyvinylidene difluoride membranes (EDM Millipore). Following blocking with 5% non-fat milk for 1 h at room temperature, the membranes were incubated overnight at 4°C with primary antibodies including anti-light chain (LC)3B (1:1,000, cat. no. ab48394; Abcam), anti-p62 (1:1,000, cat. no. ab56416; Abcam), anti-phosphorylated glycogen synthase kinase-3β (1:1,000, pGSK3β; cat. no. ab75745; Abcam), anti-GSK3β (1:1,000, cat. no. ab131356; Abcam), anti-nuclear factor (erythroid-derived 2)-like 2 (Nrf2; 1:1,000, cat. no. 16396-1-AP; ProteinTech Group, Inc.), anti-heme oxygenase 1 (HO-1; 1:1,000, cat. no. ab13243; Abcam), anti-PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α; 1:1,000, cat. no. ab54481; Abcam), β-actin (1:5,000, Santa Cruz Biotechnology, Inc.), GAPDH (1:10,000, cat. no. 10494-1-AP; ProteinTech Group, Inc.) and SOD-2 (1:1,500, cat. no. sc-137254; Santa Cruz Biotechnology, Inc.), followed by incubation with anti-rabbit (1:5,000, SA00001-2, ProteinTech Group, Inc.) or anti-mouse (1:5,000, cat. no. sc-2005, Santa Cruz Biotechnology, Inc.) horseradish peroxidase-conjugated secondary antibodies. Bands were detected by chemiluminescence technology using enhanced chemiluminescence advance Western blotting detection reagents (FD8020, Fdbio Science), quantified and normalized to β-actin or GAPDH using ImageJ 1.48v (National Institutes of Health) by an experimenter blinded to group allocation.

**Statistical analysis.** Data were expressed as the mean ± SD. Differences within multiple groups were examined by two-way ANOVA followed by the Bonferroni post hoc test. Statistical analyses were conducted using SPSS 20.0 (IBM Corp.) and GraphPad Prism 5.0 (GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.
Results

Spinosin or 6′′-feruloylspinosin treatment reduces cardiac troponin level and LDH activity in sera from AMI rats. To explore the cardioprotective effects of spinosin and 6′′-feruloylspinosin, a rat model of AMI and reperfusion was constructed. TTC staining and electrocardiogram were used to monitor and confirm the success of myocardial infarction model (Fig. S1). The present results suggested that myocardial infarction induced notable increases in cardiac troponin I (cTnl) level and LDH activity (P<0.01; Fig. 2). In addition, both spinosin and 6′′-feruloylspinosin could significantly reduce the serum levels of cTnl (from 662.0 to 402.7 and 429.2 pg/ml, respectively; P<0.01; Fig. 2A) and the activities of LDH (61286 to 42516 and 48270 u/ml, respectively; P<0.01; Fig. 2B) in AMI model rats.

ZSC flavonoids treatment reduces heart tissue injury and myocardial cell apoptosis in AMI rats. Next, following ischemia-reperfusion, the hearts were used to compare the tissue injury and cell apoptosis in different groups. HE staining results demonstrated that myocardial cells from sham operative rats were regularly arranged, associating with intact muscle fibers, while no cell edema or cell death was observed (Fig. 3A). In AMI rats treated with vehicle, however, some myocardial cells presented edema and death, accompanied by local hemorrhage and neutrophil infiltration (Fig. 3B). These pathological features were attenuated after treatment with spinosin or 6′′-feruloylspinosin (Fig. 3C and D).

Whether the regulation of cell apoptosis program participated in the cardioprotective effects was subsequently examined. As shown in Fig. 4, ~55.3% apoptotic myocardial cells were observed in vehicle treated AMI rats, and the rate was reduced to 39.0 and 38.1% after treatment by spinosin and 6′′-feruloylspinosin, respectively (P<0.01; Fig. 4B). Taken together, the present results suggested that flavonoids in ZSC could protect heart against acute ischemia-reperfusion damage.

Spinosin or 6′′-feruloylspinosin treatment can promote cell autophagy and reduce the phosphorylation of GSK3β in AMI rats. Pharmacological modulation of autophagy has been shown to affect disease outcome in a rodent model of myocardial infarction (14). Therefore, in the present study, the autophagy markers and relevant regulatory molecules were examined in various experimental groups. The present results suggested that spinosin and 6′′-feruloylspinosin increased the level of LC3B-II, while 6′′-feruloylspinosin could decrease p62, compared with vehicle control, determined by western blot analysis of infarct myocardial tissues (Fig. 5A and B), indicating they may promote cell autophagy of myocardial cells in AMI rats.

Inhibiting the phosphorylation of GSK3β at Tyrosin216 can significantly increase the basal autophagy via AMP activated protein kinase-dependent pathway (15). pGSK3β and total GSK3β were then immune-blotted with specific antibodies, and phosphorylation of GSK3β was increased up to 6 times compared with the sham control (P<0.01), and decreased after treatment of spinosin or 6′′-feruloylspinosin (P<0.01; Fig. 5C).

Spinosin or 6′′-feruloylspinosin treatment enhances the expressions of PGC-1α, Nrf2 and HO-1 in AMI rats. Evidence has shown the importance of GSK3β in ischemia-reperfusion pathologies of heart, not only effects autophagy, but also regulates multiple downstream cell-protective signal molecules, including PGC-1α, Nrf2, HO-1 and SOD2 (16). Therefore, the expressions of these molecules in samples from different groups were detected. As shown in Fig. 6, the expressions of Nrf2 and PGC-1α were decreased in the AMI model group compared with the sham group, and clearly increased by spinosin or 6′′-feruloylspinosin treatment (P<0.01). The expression of HO-1 was also significantly induced (Fig. 6C). Notably, 6′′-feruloylspinosin had higher efficiency to induce the expressions of PGC-1α, Nrf2 and HO-1. However, SOD-2 expression exhibited no obvious change after drug treatment (Fig. 6D).

Discussion

To the best of our knowledge, this is the first study to report that spinosin and 6′′-feruloylspinosin, two C-glycoside flavonoids...
from SZS, could protect the heart against ischemia-reperfusion injury in a rat model AMI. It was found that they could significantly attenuate myocardial tissue injury and reduce myocardial enzyme release and cell apoptosis. In addition, they could promote autophagy flux and increase the levels of PGC1α, Nrf2 and HO-1, which may be related to the reduction of phosphorylation of GSK3β. The present study not only improves the current understanding of the cardioprotective

Figure 3. HE staining assay showing SP and FS ameliorated tissue injury in hearts isolated from rats with myocardial infarction. (A) HE staining graphs in Sham group. Myocardial cells were regular and neatly arranged, muscle fibers were intact and no cell edema or death was observed. (B) HE staining picture in Veh-treated AMI rats. Some myocardial cells demonstrated edema and death, accompanied by local hemorrhage and neutrophil infiltration. HE staining in (C) SP and (D) FS treated AMI rats. The above pathological features were attenuated after drug treatments. Graphs on right side are the amplifications of the left picture. Scale bar is 500 µm on left, and 50 µm on right. n=6 in each group. HE, hematoxylin-eosin; SP, Spinosin; FS, 6''-feruloylspinosin; AMI, acute myocardial infarction; Veh, vehicle.

Figure 4. TUNEL assay revealing SP and FS decreased apoptotic cell death in the heart after myocardial infarction. (A) TUNEL staining images and nuclei staining in each group. (B) Quantification of the percentages of positive staining cells in different groups. Scale bar is 100 µm. Data were expressed as mean ± standard deviation; n=6 in each group; *P<0.01 vs. Sham; **P<0.01 vs. Veh. SP, Spinosin; FS, 6''-feruloylspinosin; Veh, vehicle.
mechanisms of spinosin and 6''-feruloylspinosin, but also advances the current knowledge about the active ingredients of SZS with cardioprotective effects.

Previous studies have focused on the anti-anxiety and sedative effects of spinosin, probably because SZS is defined as a hypnotic-sedative herb and is usually used for the treatment of insomnia and anxiety in East Asia countries. Recently, anti-dementia, neuroprotective and neurogenesis effects have been identified by several independent groups (6-8). Considering the protection of neurons and myocardial cells usually share common mechanism, it is not surprising that, in present study, spinosin protected the heart against ischemia-reperfusion injury in AMI rats, especially when cardioprotective roles of many other herbal flavonoids are considered.
are taken into consideration (17). However, the present study extended the pharmacological view on the active ingredients in SZS and provided a potential for drug discovery in cardiovascular diseases.

Myocardial ischemia-reperfusion injury is a complicated pathophysiological process in which oxidative stress, calcium overload, inflammatory responses and myocardial apoptosis serve important roles (1,18). An excessive generation of reactive oxygen species (ROS) or free radicals, mostly in mitochondria, is a trigger factor of injury during reperfusion stage. The elevation of ROS can trigger opening of mitochondrial permeability transition pore (mPTP), which in turn amplifies ROS production (so called ROS-induced ROS production), resulting in detrimental consequences for the affected myocardial cells (19). Approaches, such as inhibition of GSK3β, that restrict mPTP induction by increasing the mPTP-ROS threshold can provide myocardial cell protection (16). In fact, GSK3β has been proved to mediate convergence of myocardial protection (16,20). Signal pathways and agents revolving around GSK3β are intensively investigated to explore the

Figure 6. Western blot analysis for determining the expressions of PGC-1α, Nrf2, HO-1 and SOD-2, downstream molecules of pGSK3β. Representative western blot results in each group showing the relative levels of (A) PGC-1α, (B) Nrf2, (C) HO-1 and (D) SOD2. Quantification of band intensities were expressed as bar graph and shown on right side. Data indicated SP and FS could increase the expressions of PGC-1, Nrf2 and HO-1, but not SOD2. Data were expressed as Mean ± standard deviation; n=6 in each group; n.s. not significant; *P<0.05, **P<0.01 vs. Sham; †P<0.05, ‡P<0.01 vs. Veh. PGC-1α, peroxisome proliferator-activated receptor γ coactivator-1α; Nrf2, nuclear factor (erythroid-derived 2)-like 2; HO-1, hemeoxygenase 1; SOD, superoxide dismutase; pGSK3β, phosphorylated glycogen synthase kinase-3β; SP, Spinosin; FS, 6''-feruloylspinosin; Veh, vehicle.
mechanisms and approaches. The present study provided evidence showing spinosin and 6''-feruloylspinosin reduced the phosphorylation of GSK3β at Tyr216, and probably thereby protected myocardial cells. Fully elucidating the mechanism requires the comparison between Szs flavonoids and specific GSK3β inhibitors.

Inhibition of GSK3β not only directly controls mPTP through interacting mitochondrial proteins, but also induces multiple cell survival pathways, including prosurvival autophagy (21) and PGC-1α/Nrf2/HO-1 (22). Autophagy is a catabolic process to degrade cellular long-lived proteins and components in lysosome, while the metabolites then can be reused as the source of energy for the synthesis of new macromolecules (23,24). Autophagy plays a critical role in myocardial survival following AMI. Natural compounds, such as berberine and salvianolic acid B, protect myocardial tissue against ischemia-reperfusion by promoting autophagy (25,26). GSK3β inhibition also promotes autophagy to protect myocardial cells (21). Following this evidence, the present study identified that both spinosin and 6''-feruloylspinosin could enhance the expression of LC3B-II, while 6''-feruloylspinosin could reduce the level of p62, indicating autophagy is activated and probably involved in cardioprotection in the AMI model. Enhanced level of LC3B-II and reduced p62 represent more cells undergoing autophagy flux. During autophagy procedures, target engulfment and sequestration depend on p62 which is degraded by autophagy after binding to LC3 during autophagosome formation and is accepted as an autophagic substrate (27). However, it is not completely clear if p62 is exclusively eliminated by autophagy or if the ubiquitin-proteasome pathway could also be involved (28). In the present study, spinosin and 6''-feruloylspinosin could enhance the expression of LC3B-II, while only 6''-feruloylspinosin could reduce the level of p62, indicating other different mechanisms might be involved in regulating autophagy flux.

PGC-1α is an inducible transcription co-activator that is involved in the repair of ROS-induced mitochondrial injury, biogenesis of mitochondria and regulation of energy metabolism (22,29). GSK3β can phosphorylate PGC-1α and promote its ubiquitin-dependent degradation, whereas GSK3β inhibition can induce the accumulation of PGC-1α to protect cells (30,31). The cytoprotective effect of PGC-1α is related to the upregulation of Nrf2, a transcription factor, followed by the transcriptional activation of anti-oxidant gene HO-1 (22), an enzyme catalyzes the degradation of pro-oxidant heme into three important antioxidant products, bilirubin, carbon monoxide and ferrous ion (32). Meanwhile, Nrf2 can also induce the expression of SOD-2. In agreement with their inhibitory roles on GSK3β, spinosin and 6''-feruloylspinosin upregulated the protein levels of PGC-1α, Nrf2 and HO-1, indicating GSK3β inhibition-mediated PGC-1α/Nrf2/HO-1 participates in the cardioprotective roles of SZS flavonoids. Changes in SOD-2 were not observed following flavonoids treatment, so presumably other unknown regulators may be involved.

Data from the present study demonstrated that 6''-feruloylspinosin had a higher efficiency on the activation of PGC-1α/Nrf2/HO-1 pathway than spinosin, although they did not have significant differences in cardioprotective effects. The distinction on regulating cell protective molecules is possibly due to the different pharmacokinetic properties. A previous study revealed that 6''-feruloylspinosin was distributed in rats faster, and was more slowly eliminated from the plasma than spinosin, with a half-life 2.25±0.52 h of 6''-feruloylspinosin, compared with the 1.39±0.11 h of spinosin (33). However, carefully comparing the protective efficiency of spinosin and 6''-feruloylspinosin requires multiple methods and dosages of drugs administration.

Finally, SZS-containing formulae are a commonly used herbal medicine for the treatment of patients with AMI and stenocardia in Traditional Chinese Medicine, and c-glycoside flavonoids are active compounds isolated from SZS. The findings of the present study can be used to understand the cardioprotective mechanisms of SZS. It is notable that formulae in Chinese Medicine contains multiple active compounds and other active compounds may also contribute to the protection of heart against myocardial ischemia-reperfusion injury. More attention should be paid to the synergetic actions of the active compounds in the medicinal herb against myocardial ischemia-reperfusion injury in future.

There are several limitations to the present study. First, cytotoxicity tests of the two drugs should be performed before an effectiveness study to ensure their safety. Secondly, myocardial ischemia-reperfusion group rats without any treatment were not added, and therefore, the effect of myocardial ischemia-reperfusion itself on the tissue injury and enzyme release was not observed. Third, the molecular mechanisms of the cardioprotective effects of spinosin and 6''-feruloylspinosin remain unclear, and it is planned to carefully investigate how the PGC-1α/Nrf2/HO-1 pathway is involved in the protective role during which the inhibitor and genetic deletion of PGC-1α would be employed.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Science and Technology Planning Project of Guangdong Province of China (grant no. 2016A020226002), the Major Projects of Industry-University-Research Collaboration Innovation, the Science and Technology Program of Guangzhou, China (grant no. 201704020042), and the Second Development of Famous Chinese Patent Medicine of Guangdong Province, China (grant no. 20174010).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

MG, PH, CL, XL, YX and SC conducted the experiments. MG and SC performed statistical analysis. YG and YJ designed the study and analyzed the data. MG, YG, and YJ wrote the manuscript. YJ gave final approval of the publication. All authors read and approved the final manuscript.
Ethics approval and consent to participate

All animal operations were approved by the Ethics committee on Animal Experiments, Southern Medical University (approval no. L2017055) and followed the National Guidelines for Animal Experimentation.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.